Prior to co-founding Medicxi, David was a venture partner with Index Ventures for four years, having joined the life sciences team in 2012.
On behalf of Index, David co-founded Epsilon-3 Bio, Methusalah Health, and XO1 (acquired by Janssen Pharmaceuticals) among other companies. Before joining Index, he founded Funxional Therapeutics and the out-sourced drug developers Total Scientific and RxCelerate. Prior to that, David led an internationally-recognised research group in Cambridge University's Department of Medicine, where he published more than 80 first author papers in leading journals including Nature, Science and Nature Medicine. David is the Chair of the Translation Awards Committee of the British Heart Foundation. He ran a widely-read blog on life sciences-related topics, DrugBaron, before moving his writings to Forbes.com, where he is a Contributor.
David has over 150 patents and patent applications in his name, and holds MA and PhD degrees in Natural Sciences from the University of Cambridge.